Curated News
By: NewsRamp Editorial Staff
December 11, 2025
TransCode & Quantum Leap Launch Trial for RNA Cancer Drug Targeting Recurrence
TLDR
- TransCode Therapeutics gains a strategic advantage by testing TTX-MC138 in the PRE-I-SPY trial, potentially positioning its RNA therapy as a leading precision treatment for colorectal cancer recurrence.
- TransCode's TTX-MC138 will be evaluated in a Phase 2a trial starting in 2026, targeting ctDNA-positive colorectal cancer patients to assess biological activity in minimal residual disease.
- This collaboration aims to develop better treatments for colorectal cancer patients at high risk of recurrence, potentially improving survival and quality of life through precision medicine.
- TransCode is pioneering an RNA therapy targeting a specific metastasis biomarker, exploring a novel approach to treat cancer that has spread at the microscopic level.
Impact - Why it Matters
This collaboration addresses a critical unmet need in cancer care: preventing recurrence in patients with minimal residual disease. For colorectal cancer patients who have undergone initial treatment but remain at high risk of relapse due to ctDNA positivity, current options are limited. A successful therapy like TTX-MC138 could transform post-treatment monitoring from passive waiting into an active intervention phase, potentially improving survival rates and quality of life. It represents a shift toward precision medicine in oncology, targeting specific biomarkers of metastasis before tumors regrow. For the biotech and investment communities, it highlights the growing pipeline of RNA-based therapeutics and strategic partnerships accelerating clinical development in high-need oncology areas.
Summary
TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company pioneering RNA-based cancer treatments, has announced a significant collaboration with Quantum Leap Healthcare Collaborative. The partnership will focus on evaluating TransCode's lead therapeutic candidate, TTX-MC138, within the innovative PRE-I-SPY Phase 2a clinical trial platform. This study, scheduled to begin in the first half of 2026 and led by Dr. Paula Pohlmann of MD Anderson Cancer Center, plans to enroll up to 45 colorectal cancer patients who are ctDNA positive following standard curative-intent therapy. The trial specifically targets the minimal residual disease setting—a critical window where recurrence risk remains high despite initial treatment, and therapeutic options are currently limited. This reflects the growing medical interest in precision treatments that can address micrometastatic disease before it becomes clinically detectable.
TTX-MC138 represents a novel approach in oncology, designed to treat metastatic tumors that overexpress microRNA-10b, a well-documented and unique biomarker of metastasis. Beyond this lead candidate, TransCode maintains a portfolio of other first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells. The company's work sits at the forefront of immunoncology and RNA therapeutics for high-risk and advanced cancers. For those seeking more details, the full press release is available via the InvestorBrandNetwork, which provides access to a vast network of wire solutions and is part of the Dynamic Brand Portfolio at IBN. This platform offers enhanced press release distribution, article syndication to over 5,000 outlets, and comprehensive social media distribution to ensure maximum reach and impact within the investment community and beyond.
The announcement was disseminated through InvestorWire, a specialized communications platform within the InvestorBrandNetwork that focuses on advanced wire-grade press release syndication. This network delivers tailored corporate communications solutions, helping companies like TransCode Therapeutics cut through information overload to achieve unparalleled recognition and brand awareness. For ongoing updates, investors can follow the latest news relating to RNAZ in the company's dedicated newsroom. This strategic use of financial communications underscores the importance of clear, widespread dissemination of clinical trial news to stakeholders, including investors, researchers, and patients awaiting new treatment options.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode & Quantum Leap Launch Trial for RNA Cancer Drug Targeting Recurrence
